Why GI symptoms are so common
GLP-1 medications work partly by slowing gastric emptying (see our glossary entry on satiation), which is also exactly why gastrointestinal side effects are the most frequently reported issue in this drug class. According to PubMed, a 2025 systematic review of GLP-1 trials in adults without diabetes found gastrointestinal adverse events in roughly 47-84% of people on GLP-1 medications, compared with 13-63% on placebo — overwhelmingly nausea, vomiting, diarrhea, and constipation (Moiz et al., Annals of Internal Medicine, 2025, DOI (external link)). The same review found that discontinuation due to side effects was still relatively uncommon (0-26%), and serious adverse events were rare (0-10%) — meaning GI symptoms are common but usually manageable, not typically dangerous.
What's typical
- Nausea is the most frequently reported symptom, especially in the days following a dose increase, and tends to be most pronounced during titration.
- Diarrhea and constipation can both occur, sometimes alternating, as gut motility adjusts.
- Vomiting is less common than nausea but not rare, particularly with faster-than-recommended dose escalation.
What tends to improve with time
For most people, GI symptoms are worst in the first weeks after starting or increasing a dose, and settle within days to a couple of weeks as the body adjusts. This is why standard titration schedules increase dose gradually rather than jumping to a target dose immediately — see our guide on if a fast escalation seems to be driving disproportionate symptoms.